Physicians' Academy for Cardiovascular Education

RAS blockade in the real world

Slides (presentation) - May 6, 2011

RAS blockade in the real world:
Clinical lessons from recent trials


Dr Peter Meredith
University of Glasgow,
Gardiner Institute, Western Infirmary
Glasgow, United Kingdom
CDMC - Munich, may 7, 2011


Click on slides to view presentation


The concept of Diabetes & CV risk: A lifetime risk challenge
The Cardiovascular Continuum
RAS Blockade Across the CV Continuum
2007 ESH/ESC Guidelines: Choice of Antihypertensive Drugs
VALUE : Odds Ratios Over Time
VALUE: Endpoints while on Monotherapy
LIFE: Primary Composite Endpoint
Risk Reduction: ARB versus Control
MOrbidity and Mortality after Stroke – Eprosartan vs. Nitrendipine in Secondary Prevention
SCOPE: First Major Cardiovascular Events in Patients with a Previous Stroke
Antagonism of Angiotensin II-Induced Effects by Candesartan and Losartan
Insurmountable and Surmountable Antagonism: Relation to Duration of Binding
A Placebo Controlled ABPM Comparison of Candesartan 8 mg and Losartan 50 mg
Candesartan Cilexetil vs Losartan : Mean Change From Baseline to Week 8 in Systolic ABP
Comparison of the Efficacy of Candesartan & Losartan: Meta-Analysis of Trials in the Treatment of Hypertension
Candesartan & Losartan-Antihypertensive Effects: Systolic BP in Direct Comparator Trials
Candesartan & Losartan-Antihypertensive Effects: Systolic BP in Direct Comparator Trials
Candesartan & Losartan-Antihypertensive Effects: Diastolic BP in Direct Comparator Trials
Potential Benefits of Additional BP Reductions
Hypothesis and Aim
Selection Method
The “Real-Life” Study: Candesartan v Losartan
Blood Pressure Reduction
Concomitant Medication
Primary Outcome: Candesartan v Losartan
Risk of Separate Endpoints
Candesartan v Losartan: Mortality in Heart Failure Patients
Candesartan v Losartan: Mortality in Heart Failure Patients
Candesartan v Losartan: Mortality in Heart Failure Patients

Share this page with your colleagues and friends: